Innovator companies should focus on innovations
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 1
Abstract
Despite biopharmaceuticals having an enormous potential value for our health, they have also become a serious threat to our healthcare systems.
Authors and Affiliations
Theodor Dingermann
Keywords
Related Articles
- EP ID EP355184
- DOI 10.5639/gabij.2012.0101.003
- Views 95
- Downloads 0
A patient-centred paradigm for the biosimilars market
The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for approval of biosimilar...
Alternative statistical strategies for biosimilar drug development
Introduction: Many regulatory authorities have published requirements for the approval of biosimilar medicinal products. However, there is no guidance on which quantitative standards should be used to define how similar...
Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective
Aim: To provide a systematic overview on: i) safety profiles; ii) pharmacokinetic parameters; and iii) regulatory framework of anti-cancer tyrosine kinase inhibitors (TKI). Methodology: Recherché of pharmakokinetic (PK)-...
Terminology for biosimilars–a confusing minefield
Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for approval. Unfortunately, inconsistency in nomenclature for biosimilars has caused confusion. This problem o...
Statin generics: no differences in efficacy after switching
A study presented at the 2010 Congress of the European Society of Cardiology, had created a considerable stir. Its abstract allegedly showed that the originator drug Lipitor was more beneficial than any of its generic st...